# A Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Participants With Early Alzheimer's Disease

> **NCT02880956** · PHASE2 · COMPLETED · sponsor: **AbbVie** · enrollment: 453 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** ABBV-8E12
- **DRUG:** placebo for ABBV-8E12

## Key facts

- **NCT ID:** NCT02880956
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01-26
- **Primary completion:** 2021-03-30
- **Final completion:** 2021-07-28
- **Target enrollment:** 453 (ACTUAL)
- **Last updated:** 2022-08-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02880956

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02880956, "A Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Participants With Early Alzheimer's Disease". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02880956. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*